NFKB1 and lung adenocarcinoma: During cancer development, uncontrolled proliferation and insensitivity to cell death are often accompanied by the activation of NF-κB signaling [33], this is reflected in a variety of cancers, including breast cancer [34], prostate cancer [35], esophageal squamous cell carcinoma [36], lymphoma [37], lung adenocarcinoma [38], etc. Abnormal NF-κB signaling also frequently leads to abnormal changes in tumor resistance, local inflammatory response, and immune microenvironment [38–41].